Adding Avastin to the current standard of care for newly diagnosed aggressive brain cancer (glioblastoma multiforme, GBM) can significantly extend the time people live without their disease worsening, by 4.4 months (progression free survival of 10.6 months compared to 6.2 months with radiation and chemotherapy plus placebo, HR =0 .64, p Data from the phase III AVAglio trial, which evaluated Avastin in combination with standard treatment (radiation and a chemotherapy called temozolomide) was presented for the first time at the Society for Neuro-Oncology (SNO) Annual Meeting in Washington...
More...
More...